Vicriviroc Malate

Description	Vicriviroc has a higher binding affinity to CCR5 as opposed to SCH-C in competition binding assays. Vicriviroc is close to 6-fold less active than SCH-C in attenuating hERG current among In voltage-clamped L929 cells. Vicriviroc inhibits GTPγS binding to the membranes from HTS-hCCR5 cells induced by RANTES. Vicriviroc displays potent antiviral activity against a panel of 30 R5-tropic HIV-1 isolates. Vicriviroc possibly targets an early step in the viral life cycle prior to reverse transcription and virion maturation.
Pathways	GPCR/G Protein
Targets	CCR

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.